trending Market Intelligence /marketintelligence/en/news-insights/trending/IARBwg5c-WKHSdBVNNvauQ2 content esgSubNav
In This List

Pacgen, General Biologicals add new markets for P113 products

Blog

Insight Weekly: Ukraine war impact on mining; US bank growth slowdown; cloud computing headwinds

Blog

Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall

Blog

Global M&A By the Numbers: Q1 2022

Blog

Insight Weekly: Challenges for European banks; Japan's IPO slowdown; carmakers' supply woes


Pacgen, General Biologicals add new markets for P113 products

Pacgen Life Science Corp. partner General Biologicals Corp. added new markets for P113 oral and general hygiene products licensed from Pacgen.

The P113 mouth rinse and mouth sprays will be made available in southern China in addition to their existing markets in Taiwan, subject to regulatory approval.

General Biologicals entered into an agreement with Dongguan Biotech Industrial Development Co. to distribute its oral hygiene and hepatitis-testing products. It granted Dongguan Biotech exclusive right to distribute its products in the Guangdong Province.

In exchange for the regional distribution right, General Biologicals will receive up to 4.5 million Chinese yuan of milestone payments for the first year. Pacgen is entitled to royalties based on sales of P113 products, in accordance with its licensing agreement with General Biologicals.

As of Jan. 23, US$1 was equivalent to 6.86 yuan.